tbuckley/cabot-search huggingface dataset:
Pulmonary Venous Remodeling in Pulmonary Hypertension
Authors: Jane A. Leopold
Journal: Circulation (2018)

Article, see p 1796 

There is a complex relationship between pulmonary vascular remodeling and pulmonary hypertension with structural and functional changes in the vasculature being causal for, or occurring as a consequence of, elevated filling pressures in the cardiopulmonary system. Owing to this interplay, the primary pathology (pulmonary vascular versus cardiac) and resultant pulmonary hypertensive hemodynamic profile may both be key determinants of the location and the extent of architectural changes in the pulmonary vasculature. Although the pulmonary arterial and venous vessels form a contiguous unobstructed structure, it is well recognized that the genetic, molecular, and metabolic factors or exposures that initiate pulmonary vascular remodeling have a propensity to target either the arteries or the veins, preferentially.1,2 For example, in pulmonary arterial hypertension, the distal pulmonary arteries develop intimal and medial hypertrophy, fibrosis, inflammation, and thrombosis in situ, while the pulmonary veins are spared.1,2 In contrast, in pulmonary veno-occlusive disease, these pathological changes are restricted to pulmonary veins with the observed effect on pulmonary arteries considered a secondary finding.1,2 The aberrant structural remodeling characteristic of these pulmonary vascular diseases creates a segment of increased resistance in the cardiopulmonary circuit that ultimately leads to the hemodynamic findings consistent with pulmonary hypertension, which are discoverable clinically during invasive interrogation. These elevated filling pressures, in turn, may modulate disease progression via pressure- or flow-related compensatory remodeling in previously unaffected parts of the pulmonary vascular tree, as well as the right ventricle. Thus, while pulmonary arterial hypertension and pulmonary veno-occlusive disease are diseases of the pulmonary arteries and pulmonary veins, respectively, they are illustrative of the fact that vascular remodeling and cardiopulmonary hemodynamics serve as interrelated …
Eliminating Wasteful Health Care Spending—Is the United States Simply Spinning Its Wheels?
Authors: Jose F. Figueroa, Rishi K. Wadhera, Ashish K. Jha
Journal: JAMA Cardiology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Liver metastases (LM) from intrahepatic cholangiocarcinoma (iCCA): Outcomes from the European Network for the study of cholangiocarcinoma (ENS-CCA) registry and implications on current American Joint Committee on Cancer (AJCC) staging
Authors: A. Lamarca, A. Santos, K. Utpatel, A. La Casta, S. Stock, A. Forner, J. Adeva Alfonso, T. Folseraas, L. Fabris, R. Macias, M. Krawczyk, M. Krawczyk, V. Cardinale, C. Braconi, D. Alvaro, M. Evert, J. Bañales, J.W. Valle
Journal: Annals of Oncology (2019)
Prognostic role of blood cell count-based immuno-inflammatory parameters in the Valentino trial
Authors: G. Fuca, V. Guarini, S. Corallo, S. Lonardi, A. Raimondi, G. Peverelli, L. Rimassa, C. Antoniotti, R. Murialdo, A. Zaniboni, A. Sartore-Bianchi, G. Tomasello, P. Racca, M. Clavarezza, V. Adamo, M. Prisciandaro, F. Palermo, M Di Bartolomeo, F.G.M. De Braud, F. Pietrantonio
Journal: Annals of Oncology (2019)
Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models
Authors: A. Fiascarelli, G. Merlino, S. Capano, A. Paoli, A. Bressan, M. Bigioni, M. Scaltriti, J. Arribas, C. Bernadó Morales, A. Pellacani, M. Salerno, M. Binaschi
Journal: Annals of Oncology (2019)
First-line ceritinib versus chemotherapy in patients (pts) with advanced ALK rearranged (ALK+) non-small cell lung cancer (NSCLC): ASCEND-4 Asian subgroup analysis
Authors: D.S. Tan, S. Geater, C.J. Yu, C.M. Tsai, T.C. Hsia, J. Zhou, J. Chen, M.C. Lin, P. Yu, J. He, W. Li, Y. Lu, V. Sriuranpong, C.T. Yang, P. Sen, F. Branle, M. Shi, Y.L. Wu
Journal: Annals of Oncology (2019)
Phase II study of gemcitabine (Gem) and trastuzumab (T) combination therapy in first line metastatic breast cancer (MBC) patients (pts) with HER2 overexpression
Authors: A. M. Brufsky, K. Fox, M. Orlando, J. Abraham, E. Tan-Chiu, L. Haney, Y. Wang
Journal: Journal of Clinical Oncology (2006)

10591 Background: Phase III studies have demonstrated that the addition of T to chemo is associated with higher response rates (RR), improved time-to-progression (TTP) and improved overall survival in pts with metastatic HER2+ tumors. The greatest benefit from T-based therapy is found in women with pronounced HER2 overexpression (FISH+ or IHC 3+). Preclinical models suggest that Gem+T appear to be additive or synergistic. The present study was designed to determine overall RR (primary endpoint), TTP, OS and the toxicity profile of the combination of Gem+T as first-line therapy for MBC pts. Methods: Pts with measurable HER2-overexpressing (IHC 3+ or FISH+) MBC, no prior chemo in the metastatic setting (adjuvant was allowed), adequate end-organ function and PS 0–2, received Gem 1,250 mg/m 2 on days 1 and 8 and T on day 1 (8 mg/kg over 90 min on cycle 1, then 6 mg/kg over 30 min on subsequent cycles) of a 21-day cycle, until progressive disease or undue toxicity. A Simon’s optimal two-stage design was used with a total sample size of 66 (25 patients treated in the first stage and 41 additional patients in the second stage). Results: Sixty-six patients have been treated and results are available for sixty-four patients. Median age: 53 years (range 34–83); Race: Caucasian/Other 88%/12%. ER status positive/negative: 53%/47%. HER2 status IHC 3+/FISH+: 58/20 pts.; ECOG PS 0/1/2: 66%/30%/3%; Prior adjuvant therapy: Chemo 39 pts (prior anthra 31, prior taxane 21), Hormonal 32 pts (6 adj, 18 met, 8 both). Total number of cycles = 396; median = 6 (range 1–21). Toxicity was generally modest. Grade 3/4 neutropenia occurred in 11 pts (17%)/7 pts (11%); thrombocytopenia 3pts (5%)/1pt (2%), anemia 3 pts (4.7%)/ 0 pts, and 2 pts with grade 4 transaminase elevation, grade 3 elevated ALT 6 pts (9.4%); no other grade 4 toxicities were recorded. One pt with prior anthra exposure had a grade 2 decrease in left ventricular ejection fraction; no symptomatic cardiac toxicity was recorded. Best Overall RR assessment (N = 64): CR 8 (12.5%), PR 26 (40.6%) for an overall RR of 53.1% (95% CI: 40%-66%). TTP median 6 mo (95% CI: 4.4 -9.7 mo). Survival data not mature at this time. Conclusions: The combination of Gem+T in front-line MBC shows a high response rate with modest toxicity. [Table: see text]
Mutation tracking in circulating tumour DNA (ctDNA) detects minimal residual disease (MRD) in patients with localized colorectal cancer (CRC) and identifies those at high risk of recurrence regardless of stage, lack of CDX2 expression and CMS subtype
Authors: N Tarazona Llavero, F. Gimeno-Valiente, V. Gambardella, M. Huerta, S Rosello Keranen, G. Bruixola, E. Fontana, C Martinez Ciarpaglini, S. Zuñiga, P. Rentero, T. Fleitas, F. Papaccio, D. Moro, V. Pla, G. Nyamundanda, J. Castillo, A. Sadanadam, A. Espí, D. Roda, A. Cervantes
Journal: Annals of Oncology (2019)
Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer
Authors: D.M. Hyman, C.M. van Tilburg, C.M. Albert, D.S.W. Tan, B. Geoerger, A.F. Farago, T.W. Laetsch, S. Kummar, F. Doz, U.N. Lassen, S.G. DuBois, R. McDermott, L. Mascarenhas, J.D. Berlin, E.R. Rudzinski, M.C. Cox, S. Nanda, B.H. Childs, A. Drilon, D.S. Hong
Journal: Annals of Oncology (2019)
Higazi AA, Cines DB. Nuclear translocation of urokinase-type plasminogen activator
Authors: V. Stepanova, T. Lebedeva, A. Kuo, S. Yarovoi, S. Tkachuk, S. Zaitsev, K. Bdeir, I. Dumler, M. Marks, Y. Parfyonova, V. Tkachuk, B. activator
Journal: Blood (2008)
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor: Exploratory analysis in the patients who were enrolled in JCOG0705/KGCA01 phase III trial (REGATTA) and could continue chemotherapy
Authors: T. Yoshikawa, K. Fujitani, H.-K. Yang, J. Mizusawa, M. Terashima, T. Tsujinaka, K. Nakamura, H. Katayama, S.-H. Jin, S.-H. Kong, Y. Iwasaki, H.-H. Kim, A. Takagane, S.-H. Lee, J.-M. Bae, S.H. Noh, M. Sasako
Journal: Annals of Oncology (2019)
Identification of a radio-immune signature with high prognostic value in surgically resected NSCLC
Authors: G. Mazzaschi, F. Quaini, G. Milanese, L. Gnetti, G. Bocchialini, L. Ampollini, R. Minari, M. Silva, N. Sverzellati, G. Roti, M. Tiseo
Journal: Annals of Oncology (2019)
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer
Authors: Gonzalo Recondo, Laura Mezquita, Francesco Facchinetti, David Planchard, Anas Gazzah, Ludovic Bigot, Ahsan Z. Rizvi, Rosa L. Frias, Jean Paul Thiery, Jean-Yves Scoazec, Tony Sourisseau, Karen Howarth, Olivier Deas, Dariia Samofalova, Justine Galissant, Pauline Tesson, Floriane Braye, Charles Naltet, Pernelle Lavaud, Linda Mahjoubi, Aurélie Abou Lovergne, Gilles Vassal, Rastilav Bahleda, Antoine Hollebecque, Claudio Nicotra, Maud Ngo-Camus, Stefan Michiels, Ludovic Lacroix, Catherine Richon, Nathalie Auger, Thierry De Baere, Lambros Tselikas, Eric Solary, Eric Angevin, Alexander M. Eggermont, Fabrice Andre, Christophe Massard, Ken A. Olaussen, Jean-Charles Soria, Benjamin Besse, Luc Friboulet
Journal: Clinical Cancer Research (2019)

Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside compound mutations in the ALK kinase domain, other resistance mechanisms driving lorlatinib resistance remain unknown. We aimed to characterize the mechanisms of resistance to lorlatinib occurring in patients with ALK-rearranged lung cancer and design new therapeutic strategies in this setting.Resistance mechanisms were investigated in 5 patients resistant to lorlatinib. Longitudinal tumor biopsies were studied using high-throughput next-generation sequencing. Patient-derived models were developed to characterize the acquired resistance mechanisms, and Ba/F3 cell mutants were generated to study the effect of novel ALK compound mutations. Drug combinatory strategies were evaluated in vitro and in vivo to overcome lorlatinib resistance.Diverse biological mechanisms leading to lorlatinib resistance were identified. Epithelial-mesenchymal transition (EMT) mediated resistance in two patient-derived cell lines and was susceptible to dual SRC and ALK inhibition. We characterized three ALK kinase domain compound mutations occurring in patients, L1196M/D1203N, F1174L/G1202R, and C1156Y/G1269A, with differential susceptibility to ALK inhibition by lorlatinib. We identified a novel bypass mechanism of resistance caused by NF2 loss-of-function mutations, conferring sensitivity to treatment with mTOR inhibitors.This study shows that mechanisms of resistance to lorlatinib are diverse and complex, requiring new therapeutic strategies to tailor treatment upon disease progression.
Is Initial CD3+ T Cell Dose in Donor Lymphocyte Infusion for Relapsed Hematological Malignancies a Prognostic Determinant?
Authors: Erden Atilla, Pinar Ataca, Selami Kocak Toprak, Meltem Kurt Yuksel, Pervin Topcuoglu, Onder Arslan, Muhit Ozcan, Taner Demirer, Osman Ilhan, Meral Beksac, Hamdi Akan, Gunhan Gurman, Sinem Civriz Bozdag
Journal: Blood (2015)
Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)
Authors: D. Schadendorf, J.C. Hassel, M. Fluck, T. Eigentler, C. Loquai, M. Berneburg, R. Gutzmer, F. Meier, P. Mohr, A. Hauschild, J.C. Becker, C. Menzer, F. Kiecker, E. Dippel, J.-C. Simon, B. Conrad, C. Garbe, S. Körner, E. Livingstone, L. Zimmer
Journal: Annals of Oncology (2019)

Background: Risk of recurrence and death remain high for pts with advanced melanoma after resection.TVEC, an intralesional immunotherapy for advanced melanoma, selectively replicates in tumors and enhances systemic antitumor immune response.We examined the impact of neo T-VEC in resectable metastatic melanoma.Methods: Pts with resectable stage IIIB-IVM1a melanoma and 1 injectable cutaneous, subcutaneous or nodal lesions were randomized 1:1 to 6 doses/12 wks of neo T-VEC then surg (Arm 1) vs surg alone (Arm 2).T-VEC was given until surg, no remaining injectable tumors or intolerance.The primary endpoint per protocol was recurrence-free survival (RFS) at 2-yrs, with events defined as first of local, regional or distant recurrence or death due to any cause after surg in the ITT set.Per protocol, pts who withdrew prior to surg or had a non-R0 resection were counted as an RFS event at randomization.An additional sensitivity analysis that did not count non-R0 events at baseline per conventional RFS calculation was also conducted.Results: Demographics, tx status and safety for the 150 pts analyzed has been reported (Dummer et al., ASCO 2019).Median follow-up (range) was 31.2 (0.1, 49.9) mos.Per protocol, 29.5% of pts in Arm 1 and 16.5% of pts in Arm 2 remained recurrence free at 2 yrs (HR 0.75, P ¼ 0.07).50.5% of pts in Arm 1 and 30.2% of pts in Arm 2 (HR 0.66, P ¼ 0.038) remained recurrence free at 2 yrs in the additional sensitivity analysis.2-yr overall survival (OS) rates were 88.9% in Arm 1 and 77.4% in Arm 2 (overall HR 0.49, P ¼ 0.050).In Arm 1, T-VEC resulted in a 3x increase in intratumoral CD8þ cell density (P < 0.001) and an increase in PD-L1 (P 0.05).CD8þ density and PD-L1 Hscore were higher post-tx in Arm 1 vs Arm 2 (P < 0.001).Increased intratumoral CD8þ density post-tx correlated with longer RFS in the sensitivity analysis and OS.Conclusions: In the largest randomized trial of neo tx in resectable stage IIIB-IVM1a melanoma, neo T-VEC improved 2-yr RFS and OS.T-cell influx and PD-L1 upregulation after T-VEC tx support a role for the adaptive immune system consistent with the mechanisms of action.
Effects of levosimendan on respiratory muscle function in patients weaning from mechanical ventilation
Authors: Lisanne Roesthuis, Hans van der Hoeven, Christer Sinderby, Tim Frenzel, Coen Ottenheijm, Laurent Brochard, Jonne Doorduin, Leo Heunks
Journal: Intensive Care Medicine (2019)

Respiratory muscle weakness frequently develops in critically ill patients and is associated with adverse outcome, including difficult weaning from mechanical ventilation. Today, no drug is approved to improve respiratory muscle function in these patients. Previously, we have shown that the calcium sensitizer levosimendan improves calcium sensitivity of human diaphragm muscle fibers in vitro and contractile efficiency of the diaphragm in healthy subjects. The main purpose of this study is to investigate the effects of levosimendan on diaphragm contractile efficiency in mechanically ventilated patients. In a double-blind randomized placebo-controlled trial, mechanically ventilated patients performed two 30-min continuous positive airway pressure (CPAP) trials with 5-h interval. After the first CPAP trial, study medication (levosimendan 0.2 µg/kg/min continuous infusion or placebo) was administered. During the CPAP trials, electrical activity of the diaphragm (EAdi), transdiaphragmatic pressure (Pdi), and flow were measured. Neuromechanical efficiency (primary outcome parameter) was calculated. Thirty-nine patients were included in the study. Neuromechanical efficiency was not different during the CPAP trial after levosimendan administration compared to the CPAP trial before study medication. Tidal volume and minute ventilation were higher after levosimendan administration (11 and 21%, respectively), whereas EAdi and Pdi were higher in both groups in the CPAP trial after study medication compared to the CPAP trial before study medication. Levosimendan does not improve diaphragm contractile efficiency.
Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Authors: E.M. Galan-Moya, M. Nuncia-Cantarero, L. Serrano-Oviedo, S. Morcillo-García, C. Nieto-Jiménez, M. Burgos, B. Győrffy, A. Ocaña
Journal: Annals of Oncology (2019)
Spread of tumour and adverse events after modified radical hysterectomy for FIGO Stage IB1 cervical cancer patients with tumour diameter preoperatively estimated 2 cm or less: Japan Clinical Oncology Group trial (JCOG1101); exploratory analysis before primary analysis
Authors: T. Arimoto, K. Takahiro, T. Toita, H. Kobayashi, R. Machida, T. Mizutani, T. Onda, M. Mizuno, H. Yokota, S. Kamiura, K. Takehara, H. Takano, T. Saito, M. Mandai, T. Satoh, S. Yamaguchi, T. Nakamura, K. Ushijima, D. Aoki, N. Yaegashi
Journal: Annals of Oncology (2019)
Salivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: Possible relationship with oral mucositis
Authors: L. Corrêa, L.M. Bezinelli, F.C.P. Rosin, M.H. Ferreira, D.L.C. Carvalho, R M D G Lopes, N. Hamerschlak, F.D.P. Eduardo
Journal: Annals of Oncology (2019)
Excellent CBR and prolonged PFS in non-squamous NSCLC with oral CA-170, an inhibitor of VISTA and PD-L1
Authors: V. Radhakrishnan, S. Banavali, S. Gupta, A. Kumar, C.D. Deshmukh, S. Nag, S.K. Beniwal, M. Gopichand, R. Naik, K.C. Lakshmaiah, D. Mandavia, M. Ramchandra, K. Prabhash
Journal: Annals of Oncology (2019)
<i>ARID5B</i> Influences Antimetabolite Drug Sensitivity and Prognosis of Acute Lymphoblastic Leukemia
Authors: Heng Xu, Xujie Zhao, Deepa Bhojwani, Shuyu E, Charnise Goodings, Hui Zhang, Nita L. Seibel, Wentao Yang, Chunliang Li, William L. Carroll, William E. Evans, Jun J. Yang
Journal: Clinical Cancer Research (2019)

Treatment outcomes for childhood acute lymphoblastic leukemia (ALL) have improved steadily, but a significant proportion of patients still experience relapse due to drug resistance, which is partly explained by inherited and/or somatic genetic alternations. Recently, we and others have identified genetic variants in the ARID5B gene associated with susceptibility to ALL and also with relapse. In this study, we sought to characterize the molecular pathway by which ARID5B affects antileukemic drug response in patients with ALL.We analyzed association of ARID5B expression in primary human ALL blasts with molecular subtypes and treatment outcome. Subsequent mechanistic studies were performed in ALL cell lines by manipulating ARID5B expression isogenically, in which we evaluated drug sensitivity, metabolism, and molecular signaling events.ARID5B expression varied substantially by ALL subtype, with the highest level being observed in hyperdiploid ALL. Lower ARID5B expression at diagnosis was associated with the risk of ALL relapse, and further reduction was noted at ALL relapse. In isogenic ALL cell models in vitro, ARID5B knockdown led to resistance specific to antimetabolite drugs (i.e., 6-mercaptopurine and methotrexate), without significantly affecting sensitivity to other antileukemic agents. ARID5B downregulation significantly inhibited ALL cell proliferation and caused partial cell-cycle arrest. At the molecular level, the cell-cycle checkpoint regulator p21 (encoded by CDKN1A) was most consistently modulated by ARID5B, plausibly as its direct transcription regulation target.Our data indicate that ARID5B is an important molecular determinant of antimetabolite drug sensitivity in ALL, in part, through p21-mediated effects on cell-cycle progression.
High circulating miR-1247 is a marker for poor prognosis in patients with metastatic colorectal cancer treated with chemotherapy and cetuximab
Authors: J.V. Schou, Z. Sztupinszki, J.S. Johansen, D.L. Nielsen, B. Glimelius, C. Qvortrup, H. Sorbye, B Vittrup Jensen, P. Pfeiffer
Journal: Annals of Oncology (2019)
Randomized phase II trial of CAPOX with planned oxaliplatin stop-and-go strategy as adjuvant chemotherapy after curative resection of colon cancer (CCOG-1302 study)
Authors: H. Yokoyama, G. Nakayama, K. Ishigure, N. Hayashi, K. Tanaka, M. Tsutsuyama, N. Hattori, S. Yamada, Y. Kodera
Journal: Annals of Oncology (2019)
Medical Costs Among Youth Younger Than 20 Years of Age With and Without Diabetic Ketoacidosis at the Time of Diabetes Diagnosis
Authors: Sharon H. Saydah, Sundar S. Shrestha, Ping Zhang, Xilin Zhou, Giuseppina Imperatore
Journal: Diabetes Care (2019)

OBJECTIVE While diabetic ketoacidosis (DKA) is common in youth at the onset of the diabetes, the excess costs associated with DKA are unknown. We aimed to quantify the health care services use and medical care costs related to the presence of DKA at diagnosis of diabetes. RESEARCH DESIGN AND METHODS We analyzed data from the U.S. MarketScan claims database for 4,988 enrollees aged 3–19 years insured in private fee-for-service plans and newly diagnosed with diabetes during 2010–2016. Youth with and without DKA at diabetes diagnosis were compared for mean health care service use (outpatient, office, emergency room, and inpatient visits) and medical costs (outpatient, inpatient, prescription drugs, and total) for 60 days prior to and 60 days after diabetes diagnosis. A two-part model using generalized linear regression and logistic regression was used to estimate medical costs, controlling for age, sex, rurality, health plan, year, presence of hypoglycemia, and chronic pulmonary condition. All costs were adjusted to 2016 dollars. RESULTS At diabetes diagnosis, 42% of youth had DKA. In the 60 days prior to diabetes diagnosis, youth with DKA at diagnosis had less health services usage (e.g., number of outpatient visits: −1.17; P &amp;lt; 0.001) and lower total medical costs (−$635; P &amp;lt; 0.001) compared with youth without DKA at diagnosis. In the 60 days after diagnosis, youth with DKA had significantly greater health care services use and health care costs ($6,522) compared with those without DKA. CONCLUSIONS Among youth with newly diagnosed diabetes, DKA at diagnosis is associated with significantly higher use of health care services and medical costs.
Pembrolizumab for recurrent/metastatic cutaneous squamous cell carcinoma (cSCC): Efficacy and safety results from the phase II KEYNOTE-629 study
Authors: J.J. Grob, R. Gonzalez Mendoza, N. Basset-Seguin, O. Vornicova, J. Schachter, A. Joshi, N. Meyer, F. Grange, J.M. Piulats, J. Bauman, P. Zhang, B. Gumuscu, R.F. Swaby, B.G.M. Hughes
Journal: Annals of Oncology (2019)
A High-Risk Multiple Myeloma Group Identified By Integrative Multi-Omics Segmentation of Newly Diagnosed Patients
Authors: Maria Ortiz, Fadi Towfic, Mehmet Kemal Samur, Erin Flynt, In Sock Jang, Kai Wang, Cody Ashby, Brian A Walker, Matthew Trotter, Gareth Morgan, Nikhil Munshi, Anjan Thakurta
Journal: Blood (2018)